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Autism spectrum disorders (ASD) are characterised by impairments in social 
interaction and communication, and repetitive and compulsive behaviours. The 
heterogeneous nature of ASD is underpinned by complex genetic networks; hence 
there is no known single genetic cause of ASD.  It is therefore imperative to identify 
both genetic and epigenetic loci associated with ASD or specifically ASD 
endophenotypes. This may aid in earlier interventions for ASD if molecular 
biomarkers were identified. The serotonergic system has a longstanding association 
with ASD, and the differential expression of the serotonin transporter gene (SLC6A4) 
is linked to particular ASD traits. This study focuses on a length polymorphic repeat 
region (5-HTTLPR) upstream of the SLC6A4 promoter, and SLC6A4 promoter DNA 
methylation. The short variant of 5-HTTLPR is directly linked to lowered SLC6A4 
expression and is at higher frequencies in ASD populations. DNA methylation at the 
promoter of SLC6A4 is also known to affect SLC6A4 expression. 
 
This study hypothesis is that there is differential regulation of SLC6A4, through 
changes in 5-HTTLPR and DNA methylation, between an ASD and control cohort. 
This differential regulation was also predicted to differ between ASD 
endophenotypes based on severity levels categorised by ADOS-2 (Autism 
Diagnostic Observation Schedule-2). ASD children (n=50) were compared to an age-
matched control group (n=13), all of whom were characterised phenotypically by an 
ADOS-2 assessment. The 5-HTTLPR and SLC6A4 promoter DNA methylation were 
analysed using restriction fragment length polymorphic analysis and the EpiTYPER 
assay, respectively. 
 
Significant differences were found in SLC6A4 regulation between the ASD and 
control group. A significant increase in frequency of individuals homozygous for the 
5-HTTLPR long variant in the control group was observed when compared to the 
ASD cohort (p=0.049); with the long allele conferring reduced risk of ASD. Overall 
DNA methylation at the SLC6A4 promoter region was significantly decreased in the 
ASD cohort (p=0.011), the moderate ASD endophenotype (p=0.004), language 
impaired endophenotype (p=0.003), as well as the more severe socially and 
repetitive and restricted behaviour groups (p=0.006 and 0.045, respectively), when 
compared to the control cohort. Reduced levels of DNA methylation at CpG 30 in the 
target region were found to be significantly associated with higher levels of repetitive 
behaviour (p=0.001). 
 
The data from this study implicates the involvement of the serotonin transporter in 
overall ASD aetiology, specifically within the language impaired and repetitive and 
restricted behaviour endophenotypes. The data highlight the importance of 
maintaining appropriate methylation levels in order to modulate SLC6A4 expression. 
The regulatory mechanisms that control DNA methylation at the SLC6A4 promoter 
are unknown and need to be identified to completely understand how dysfunction of 
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CHAPTER 1  
Introduction 
1.1. Complex phenotypes and Autism Spectrum Disorders (ASD) 
Human genetic studies on complex traits and phenotypes have primarily focussed on 
DNA sequence variants or polymorphisms, with comprehensive and curated collation 
of this data on record (Amberger et al, 2015). These polymorphisms contribute to 
conferring susceptibility to disorders, such as Fragile X syndrome and sickle cell 
anaemia (Hessl et al., 2008; Ingram, 1957), and moderate responses to targeted 
therapy. However, there has been a recent trend of analysing epigenetic regulation 
of gene expression to assess the potential interplay with environmental factors. This 
environmentally induced epigenetic regulation of genes has been observed in a 
number of complex phenotypes, such as schizophrenia (Dong et al., 2015) and other 
central nervous system disorders (Szyf, 2015). These complex phenotypes likely 
result from interplay among multiple causal genes with both epigenetic and 
environmental influences. This interplay complicates the identification of specific 
causes or exact molecular contributions towards the aetiology of certain disorders, 
resulting from the polygenic nature of these disorders (Marian, 2012). A large 
number of neuropsychiatric disorders are polygenic, such as schizophrenia and 
bipolar disorder (Neale and Sklar, 2015). These disorders display large phenotypic 
heterogeneity; this is especially true for Autism Spectrum Disorders.  
 
Autism Spectrum Disorders (ASD) encompass a range of complex neuro-
developmental disorders affecting the central nervous system (Lintas et al., 2012). 
ASD is characterised by persistent impairments in core domains of social 
communication and social interaction, as well by the presence of restricted and 
repetitive acts or behaviours. Individuals with ASD fall upon a spectrum; with various 
symptoms of ASD, such as restricted behaviour and impaired social communication, 
ranging from mild to severe. ASD is a life-long condition, typically diagnosed in early 





Global estimations place the incidence or diagnosis of ASD ranging from 0.6% to 1% 
of the population (Brugha et al., 2011; Williams et al., 2006; Elsabbagh et al., 2012; 
Sun et al., 2013; Hirtz et al., 2007), with a 4:1 male to female bias (Hirtz D et al., 
2007). Between 2002 and 2008, the prevalence of ASD increased by 78% (Autism 
and Developmental Disabilities Monitoring Network, 2008). This most likely results 
from possible inclusion of below-threshold cases, differences in methodology, 
increased awareness, as well as a true ASD incidence rise (American Psychiatric 
Association, 2013). Regardless of the cause for this increased incidence or 
diagnosis of ASD, effective alleviative treatment of ASD relies on early intervention 
methods.  
 
Early diagnosis of ASD allows for quick intervention practices leading to an 
improvement in social, communication and cognitive impairments, as well as a 
decrease in any maladaptive behaviour (Landa, 2007; Rogers and Vismara, 2008). 
However, most diagnoses occur long after symptoms have presented (Howlin and 
Asgharian, 1999; Wiggins et al., 2006). Both the diagnostic system and intervention 
services present in developing countries, such as South Africa, are limited. This 
places pressure on such services available; with data on incident rates, prevalence 
and ASD impact almost non-existent (Malcolm-Smith et al., 2013). Therefore, studies 
should focus on identifying methodology to aid in the diagnosis of ASD at earlier 
stages in children. In particular, identifying molecular biomarkers could aid in 
anticipating the specific set of impairments that could present in children. This is 
pertinent for children with ASD worldwide, but particularly in undeveloped countries, 
where resources are sorely lacking. Earlier intervention and therefore more targeted 
treatment to alleviate the negative effects of ASD are imperative. In order to 
accomplish this, one needs to address several challenges faced that come hand in 
hand with the study of ASD. 
 
Challenges of studying ASD: heterogeneity and heritability 
The main challenge of studying ASD is the phenotypic heterogeneous nature of this 
spectrum disorder. The phenotypic heterogeneity of ASD suggests a genetically 
complex molecular underpinning. Multiple genes or molecular pathways may be at 
play simultaneously, as well as in accordance with both epigenetics and 




heterogeneity complicates any genetic or biological analysis (Hu et al., 2009). 
Therefore, some studies have attempted to reduce this phenotypic heterogeneity by 
clustering the complex phenotypes into more well-defined endophenotypes based on 
ASD and trait severity (Hu et al., 2009; Hu and Steinberg, 2009). The focus of ASD 
studies would then be on ASD-like traits as opposed to ASD as a whole. This allows 
for specific characteristics of ASD to be associated with certain genetic, 
environmental or epigenetic influences and could then aid in the identification of 
genes or causal pathways. Therefore, potential biomarkers may be identified that 
could be associated with specific traits of ASD. This in turn, may contribute to the 
effectiveness of the ASD diagnostic system. 
 
The current ASD diagnostic measures rely solely on clinical diagnoses. Therefore, 
ASD diagnostic criteria rely largely on the identification of a set of observable 
characteristics (Mandy et al., 2014). This is made ambiguous by the phenotypic 
heterogeneity of ASD, as well as by ASD co-morbidities. These include depression, 
attention deficit hyperactivity disorder, speech and language development delays 
and other psychiatric disorders (Morsi et al., 2011). Due to the lack of understanding 
surrounding the molecular underpinnings of ASD, no current diagnostic biomarkers 
are applicable (Mandy et al., 2014). 
 
Another challenge of studying ASD concerns the complex nature of ASD heritability. 
Twin studies have attempted to determine the degree of heritability by examining the 
environmental and genetic factors that play a role in ASD aetiology. Certain 
monozygotic twin studies estimate that heritability is as high as 70%-90% (Robinson 
et al., 2012; Bailey et al., 1995). However, a study by Hallmayer et al. (2011) 
reported lower heritability for monozygotic twins with a probandwise concordance 
rate of 0.58. This study also reported a higher than previously reported concordance 
rate for dizygotic twins (Hallmayer et al., 2011). These reported rates suggest a 
larger role for environmental factors in ASD aetiology than initially proposed. 
Heritability estimates are further made ambiguous by other influences that may 
reduce the genetic similarity between monozygotic twins. These include de novo 
mutations, copy number variations (CNVs) and any epigenetic changes occurring in 
one twin only (Bruder et al., 2008). On the contrary, other factors work to enhance 




environment that allows for comparable epigenetic alterations (Titlestad et al., 2002). 
However, genetic polymorphisms are still considered the main contributing factor, 
with over 100 genomic loci identified with a contributory role in ASD aetiology 
(Betancur, 2011). Most genetic-based research into the aetiology of ASD, primarily 
through genome wide association studies, has not been conclusive (Newschaffer et 
al., 2007; Sykes and Lamb, 2007), likely due to the potential interplay with 
environmental factors through epigenetic mechanisms.  
 
1.2. Genetic/epigenetic interplay 
It is estimated that only 10-20% of ASD cases have known genetic causes; these 
include chromosomal abnormalities, copy number variants and single causal genes 
(Geschwind, 2011). The apparent increasing incidence of ASD cases highlights the 
value of investigating a potential interplay between the environment and genetics in 
ASD aetiology (Newschaffer et al., 2007; CDC, 2012).  This environmental 
contribution is hypothesized to act via epigenetic mechanisms. These mechanisms 
allow for reversible heritable changes that alter or regulate the expression of genes 
without changing the DNA sequence (Gropman and Batshaw, 2010). Many non-
coding DNA regions are imperative in the modulation of gene transcription and are 
often under the control of epigenetic regulation. This control is primarily observed in 
developmental cellular processes, including cell differentiation, tissue arrangement 
and the regulation of certain cell lines (Gropman and Batshaw, 2010). These 
processes result from changes in the patterns of gene expression in differing cells 
that ultimately govern a cell‘s developmental fate. Furthermore, these epigenetic 
mechanisms allow for the interplay between genetics and the environment by 
responding to various environmental cues and subsequently controlling gene 
function (Van Vliet et al., 2007). For example, an epigenetic model based on 
imprinting in Angelman and Prader-Willi syndrome, has been proposed for ASD 
aetiology (Jiang et al., 2004). Therefore, investigation of these epigenetic regulatory 
mechanisms is important to understanding the molecular basis of the development of 
ASD and ASD-like traits. The main epigenetic mechanism implicated in ASD 
aetiology is that of DNA methylation, typically observed in the promoter regions of 







DNA methylation is the covalent chemical modification of a methyl group being 
added to the 5th position of the cytosine pyridine ring (Figure 1.1). This generally 
occurs when the cytosine is positioned to the 5‘ end of a guanine; known as a CpG 
site (Dhingra et al., 2014). DNA methylation is central in the regulation of cell 
differentiation and alters protein transcription that affects downstream pathways (De 
Leon-Guerrero et al., 2011; LaSalle, 2011). This is because methylation can alter the 
interactions between DNA and proteins, ultimately leading to chromatin restructuring, 
and either an increase or decrease in transcriptional activity. The addition of the 
methyl group through DNA methylation can also allow for the binding of specific 
proteins that can then regulate transcriptional activity (Jones and Takei, 2001). CpG 
islands comprise of clustered CpG sites that are generally non-methylated (Larson et 
al., 1992), usually located upstream of the genes, or in the promoter regions (De 
Leon-Guerrero et al., 2011; LaSalle, 2011). Methylation of these regions can lead to 




Figure 1.1. Schematic diagram of the chemical conversion of a 
cytosine to 5-methyl-cytosine during DNA methylation. The 
unmethylated cytosine is to the left, while the methylated cytosine, now 






The role of DNA methylation in gene regulation has long been hypothesized as a 
contributing factor in psychiatric disorders (Tsankova et al., 2007; Grayson et al., 
2013; Mill et al., 2008). Several studies have shown that early life stress, such as 
childhood abuse, modulates regulation of gene expression via differential 
methylation patterns in the brain which can then alter behaviour (McGowan et al., 
2009; Reaume and Sokolowski, 2011). Additionally, Wong et al. (2014) completed a 
comprehensive analysis of DNA methylation between monozygotic twins discordant 
for ASD and ASD-traits, as well as between ASD cases and controls. They observed 
a greater number of CpG sites with large methylation differences between ASD-
discordant twins than within control twins. Wong et al. (2014) also observed DNA 
methylation differences between their ASD cohort and control individuals. These 
studies have provided platforms to identify various candidate genes and pathways 
implicated in the development of ASD and other neuropsychiatric disorders. 
 
Candidate genes/pathways 
Multiple genes and metabolic pathways have been implicated in ASD aetiology from 
studies of both DNA methylation regulation, and genetic polymorphisms. For 
example, a study by Zhu et al. (2014) implicated epigenetic dysregulation of 
SHANK3 in ASD individuals. SHANK3 is involved in connecting neurotransmitter 
receptors and other membrane proteins to the G-protein-coupled signalling pathways 
(Boeckers et al., 2002). This study observed significantly increased DNA methylation 
and therefore altered expression of the SHANK3 gene in 15% of brain tissue of ASD 
cases. Other studies highlighted differential DNA methylation patterns between ASD 
individuals and any non-ASD siblings (Wong et al., 2014; Nguyen et al., 2010). 
Epigenetic dysregulation of the retinoic acid-related orphan receptor alpha gene 
(RORA) within ASD was identified (Nguyen et al., 2010). RORA acts within the 
transcriptional regulation of genes involved in circadian rhythms (Ko and Takahashi, 
2006). In the first global methylation analysis of ASD using 3 pairs of monozygotic 
twins and 2 pairs of siblings, Nguyen et al. (2010) showed that increased methylation 
at the RORA promoter was responsible for decreased expression of the gene in 
ASD. This study also showed a reduction in RORA protein in post-mortem brain 
tissues in ASD individuals compared to controls (Nguyen et al., 2010). These studies 




More specifically, one of the main pathways identified in neuropsychiatric disorders, 
including ASD and ASD-like traits, involves the serotonergic system (Dolen et al., 
2013). Altered serotonergic signalling has been implicated in a variety of conditions, 
such as depression (Philibert et al., 2008), obsessive compulsive disorder 
(Voyiaziakis et al., 2011) and anxiety disorders (Katsuragi et al., 1999; Lesch et al., 
1996; Naslund et al., 2015). This supports the involvement of the serotonergic 
system within neuropsychiatric disorders. In addition, many attributes of the above 
mentioned disorders are also found in certain ASD cases, highlighting the need for 
further analysis of the role of the serotonergic system within an ASD population.  
 
1.3. Serotonergic signalling and the serotonin transporter (SLC6A4)  
Serotonin (5-HT) is an integral monoamine neurotransmitter involved in serotonergic 
signalling within the central and peripheral nervous systems. The raphe 5-HT system 
moderates mood, motor function, cognition and circadian and neuroendocrine 
rhythms. These rhythms are involved in food intake, sleep and reproductive activity 
(Heils et al., 1996). Furthermore, the serotonergic system plays an initiatory role in 
signalling during development and maturation of tissues, including regulation of 
neurite growth, neuronal differentiation and structure synaptogenesis and 
neurogenesis (Madden and Zup, 2014, and references within). Thus, the functioning 
of the serotonergic system is crucial for typical neural development. Therefore, any 
disruptions to this system may lead to susceptibility to the aforementioned 
neuropsychiatric disorders.  
 
One of the key regulators and therefore most susceptible to disrupting the 
serotonergic system is the serotonin transporter protein (Lesch et al., 1996). This 
protein, called the 5-hydroxytryptamine transporter (5-HTT) is encoded by the 
SLC6A4 (solute carrier family 6, member 4) gene. It directs the scale and duration of 
post-synaptic responses. In addition, it is involved in carrier-facilitated transport of 
serotonin in and out of the presynaptic neuron (Heils et al., 1996). The specific mode 
of action of the serotonin transporter and the location of its coding gene on 
chromosome 17 is observed in an informative diagram from Canli and Lesch (2007) 
in Figure 1.2. This diagram illustrates the main regulatory role of this transporter 




potentially through changes in serotonin transporter action, may then confer 
susceptibility to ASD and other neuropsychiatric disorders.   
 
Link to ASD 
The specific link of the serotonergic system to ASD stems from a variety of findings. 
Firstly, reduced binding of the serotonin transporter was observed in specific brain 
regions of individuals with ASD (Makkonen et al., 2008; Murphy et al., 2006). ASD 
has also had longstanding associations with several polymorphisms in genes 
working within the serotonergic system, including SLC6A4  (Huang et al., 2008; 
Kistner-Griffin et al., 2011; Guhathakurta et al., 2009; Hranilovic et al., 2010). In 
addition, a study by McDougle et al. (1996) observed increased ASD-related sensory 
motor behaviours following the depletion of tryptophan, which is involved in the 
production of serotonin. This implicates changes in behaviours associated with ASD 
with altered levels of serotonin. 
 
Other ASD behaviours, such as abnormal reciprocal social interaction and repetitive 
behaviours were also improved in some ASD cases after exposure to selective 
serotonin reuptake inhibitors (SSRIs). These act directly on the serotonin transporter 
(Gordon et al., 1993; Kolevzon et al., 2006; McDougle et al., 1996). SSRIs are 
similar in structure to serotonin, and therefore compete for binding of the serotonin 
transporter leading to an increase in the levels of synaptic serotonin. Due to the 
alleviation of ASD-related symptoms through the use of SSRIs, serotonergic system 
malfunctioning is again implicated with ASD and other psychiatric ASD comorbid 
disorders. 
 
Gastrointestinal problems are also a known comorbidity of ASD (Parracho et al., 
2005). Serotonin acts as a paracrine signalling molecule at the gastrointestinal level 
via serotonergic interneurons. Up to five types of receptors that play a role in 
intestinal peristalsis, brain-gut axis signalling and secretion are activated by 
serotonin. Thus, abnormal levels of serotonin within this system can affect all of 
these actions. This may result from the overproduction of serotonin, therefore 
excessive release, as well as inadequate uptake of serotonin and subsequent 
inactivation. Therefore, any modifications or alterations to the action of the serotonin 




In addition, the observed male to female bias of ASD may also be partially 
accounted for by improper regulation of the serotonergic system (Madden and Zup, 
2014, and references within). The modulating fundamental mechanisms by serotonin 
were established very early on and differ between males and females, with a 
sexually dimorphic profile of serotonin release and metabolism. A relatively stable 
level of serotonin is observed in the female brain in early postnatal development, 
while the male brain shows a temporary and significant decrease in serotonin 
(Giulian et al., 1973; Wilson et al., 1986). Therefore, neurological sexual 
differentiation resulting in physiological and behavioural changes relies on 
appropriate regulation of serotonin signalling. Through the introduction of SSRIs, 
increases of serotonin signalling are observed which impacts upon cellular and 
behavioural processes. This increase is more significant in males (Rodriguez-Porcel 
et al., 2011; Simpson et al., 2011). Therefore, Madden and Zup (2014) suggest that 
the developing brain of males, especially during early postnatal development, is 
more sensitive and therefore susceptible to any alterations to normal serotonin 
signalling. This in turn may be at least a contributing factor to the observed male bias 
for ASD. 
 
Lastly, one of the main linking factors of the serotonergic system to ASD involves 
elevated whole blood serotonin levels being observed in up to 35% of individuals 
with ASD (Hranilovic et al., 2007). The cause of this observed blood serotonin 
increase is unknown, but may be the result of serotonin production and metabolism 
differences of individuals during foetal development (Madden and Zup, 2014, and 
references within). These elevated levels of blood platelet serotonin have also been 
hypothesized to result from a change in the serotonin transporter and its function 
(Cook et al., 1993). 
 
Repeat polymorphism of SLC6A4 
One of the most studied polymorphisms of the serotonin transporter, which alters its 
function, is a repeat polymorphic region. This repeat polymorphism is called the 
serotonin-transporter linked polymorphic region (5-HTTLPR), and found in the 
promoter of SLC6A4 upstream of the protein coding region (Lesch et al., 1996). The 
5-HTTLPR is comprised of two variants, a short allele (S) and a 44bp longer allele 




repeat, can affect SLC6A4 mRNA expression (Delbruck et al., 1997; Heils et al., 
1996; Lesch et al., 1996). The S allele also appears to have an overriding mode of 
action compared to the L allele and therefore the genotypes SS and LS are often 
grouped together in comparison studies (Hu et al., 2006). The L allele also contains 
an A to G single nucleotide polymorphism (SNP), rs25531. The A variant (LA) is 
associated with increased SLC6A4 mRNA expression, while the G variant (LG) acts 
more similarly to the S allele. This substitution creates an allelic polymorphism with 
three potential variants (Hu et al., 2006; Wendland et al., 2006), with the frequency 




Figure 1.2. Diagram of the SLC6A4 gene and transporter function. 
Position on chromosome 17, allelic variation of the repeat polymorphic 
region (5-HTTLPR) and serotonin reuptake mechanism is shown. Image 
is taken from Canli and Lesch (2007). The S and L alleles are shown in 
blue and red, respectively. The S allele leads to lowered mRNA 
transcripts of SLC6A4 compared to the mRNA transcripts from the long 
allele. The carrier-facilitated transport of serotonin is indicated by the 







South African population based studies report an increased presence of the S allele 
in an ASD population. A study by Esau et al., (2008) reported genotypic frequencies 
of the 5-HTTLPR in a control population, with the homozygous LL individuals at 
61.40%, the LS heterozygous at 33.92% and the homozygous SS at 4.68%. A 
second study by Arieff et al., (2010) proceeded to do the same for an ASD cohort. 
They observed frequencies of 52.00% for homozygous LL individuals, 18.00% for LS 
heterozygotes and 30.00% for the homozygous SS individuals. This increased 
number of homozygous SS individuals in an ASD population suggests a role for the 
S allele, and reduced SLC6A4 function, in ASD development.  
 
The S allele has also been shown to be associated with various ASD-like traits, such 
as anxiety (Canli and Lesch, 2007; Lesch et al., 1996) and rigid and compulsive 
behaviours (Lin, 2007; McDougle et al., 1998; Sutcliffe et al., 2005). Several studies 
have attempted to identify a link between the 5-HTTLPR and ASD as a whole, but 
this has proven inconclusive. Studies have shown an association between the S 
allele and ASD (Kistner-Griffin et al., 2011; Arieff et al., 2010), while others implicate 
the L allele with ASD (Cho et al., 2007; Yirmiya et al., 2001). However, other studies 
were unable to replicate or corroborate these findings (Ma et al., 2010; Persico et al., 
2002; Ramoz et al., 2006). The difficulty in finding clear, replicable associations with 
the 5-HTTLPR may be due to the phenotypic heterogeneity of ASD. 
 
Studies have attempted to narrow these phenotypic differences using a more 
focused approach. For example, Nyffeler et al., (2014) focused their study on high 
functioning ASD cases only, with specific reference to intellectual and language 
ability, as well as cognitive function. They reported an association; with the S allele 
as a significant risk factor in ASD aetiology (Nyffeler et al., 2014). However, the lack 
of a conclusive gene variant association implicates other mechanisms, such as 
epigenetic DNA methylation, in the aetiology of ASD. 
 
Promoter DNA methylation of SLC6A4 
Studies have attempted to link the serotonergic system to ASD, and other 
neuropsychiatric disorders, not only through the 5-HTTLPR, but also by analysing 
promoter DNA methylation of the SLC6A4 gene. Interestingly, DNA methylation of 




methylation levels at birth compared to males (Philibert et al., 2008; Beach et al., 
2010). The cause of this difference and specific effects remain unclear, however this 
is in line with the involvement of DNA methylation within ASD aetiology, and the 
male bias observed. 
 
Focus has also been on how the methylation status of the SLC6A4 promoter 
interacts with the 5-HTTLPR. SLC6A4 expression is significantly moderated through 
chromatin remodelling, which includes DNA methylation of CpG cytosine residues. 
Increased CpG methylation at the promoter region found upstream of SLC6A4 has 
previously been found to correlate with reduced SLC6A4 mRNA levels (Philibert et 
al., 2007) as well as brain serotonin synthesis (Wang et al., 2012). Therefore, DNA 
methylation induces a similar effect to that observed by the presence of the S allele 
of the 5-HTTLPR. A longitudinal study by Wong et al., (2010), posited that the 
variation of DNA methylation observed at the SLC6A4 locus likely results from 
environmental factors which may account for interindividual DNA methylation 
differences. However, other studies have demonstrated that the presence of the S 
allele can influence DNA methylation levels of the SLC6A4 promoter (Philibert et al., 
2007; Vijayendran et al., 2012). This supports the notion that SLC6A4 DNA 
methylation is regulated to a certain extent by the status of the 5-HTTLPR. 
 
Furthermore, many studies have attempted to elucidate the impact of environmental 
factors on DNA methylation of SLC6A4. One study showed that higher levels of 
methylation of SLC6A4 were associated with increased adult reactivity following 
infantile exposure to early life stress in rhesus macaques (Kinnally et al., 2011). 
Beach et al. (2010) connected increased DNA methylation of the SLC6A4 promoter 
with childhood physical abuse, and this correlation was replicated in a second study 
that focused on women (Beach et al., 2011). Lower DNA methylation levels of 
SLC6A4 have also been associated with an increased susceptibility to posttraumatic 
stress disorder (PTSD). Higher DNA methylation levels create a protective effect 
against PTSD (Koenen et al., 2011). However, higher DNA methylation levels in the 
SLC6A4 promoter were also associated with increased trauma in 5-HTTLPR 
homozygous LL individuals, while fewer traumas are observed in homozygous SS 
individuals (van Ijzendoorn et al., 2010). DNA methylation of SLC6A4 has been 




(McGowan et al., 2009; Caspi et al., 2003). These studies are indicative of a more 
complex interaction between the 5-HTTLPR and environmental factors which 
influence the DNA methylation status of the SLC6A4 promoter. 
 
One of the most promising regions for potential differential DNA methylation of 
SLC6A4 that may interact with the 5-HTTLPR is shown in Figure 1.3. The relative 
position of CpG sites to the transcription start site (TSS) and 5-HTTLPR is indicated. 
This image is taken from a study by Wang et al., (2012) who analysed DNA 
methylation at the promoter of SLC6A4 and found an association with childhood 
physical aggression. This study observed hypomethylation within this CpG Island. A 
mean DNA methylation percentage ranging from 4.32% to 5.78%, depending on 
tissue type and an overall range from 1.17% to 15.89% DNA methylation was 
reported. This study also suggested a functional role of DNA methylation in SLC6A4 
promoter regulation, with in vitro methylation inducing transcriptional activity 




Figure 1.3. SLC6A4 promoter region investigated by Wang et al. 
(2012), showing positions of the CpG sites relative to the TSS and 
the 5-HTTLPR. DNA methylation at this region is associated with 
changes in SLC6A4 mRNA expression.  
 
 
The SLC6A4 promoter region is rich in CpG sites, with several CpG islands across a 
799bp stretch of DNA, comprising of 81 CpG sites (Philibert et al., 2007). A specific 
CpG-rich region contains 7 CpG sites situated between 479bp and 350bp relative to 
the transcription start site (accession number: BankIt1577778 SLC6A4 KC106430) 
that have been associated with changes in mRNA expression of SLC6A4 (Philibert 




1.4. Research Question and Study Aims 
The overarching research question of this study is whether there is differential 
molecular regulation of SLC6A4 between a) an ASD and control cohort, and b) 
different endophenotypes of ASD.  The first objective of this study was to determine 
the endophenotypes of the ASD cohort using ADOS-2 (Autism Diagnostic 
Observation Schedule-2), which provides the severity level of ASD, as well as 
individual scores for social affect (SA) and repetitive and restricted behaviour (RRB). 
Well-defined, smaller subgroupings of the ASD cohort based on these scores allow 
for easier identification of any associations between the molecular underpinnings 
and ASD trait severity. This alleviates ASD phenotypic heterogeneity difficulties, and 
will hopefully allow for the identification of causal mechanisms for ASD traits. This 
may then inform preventative or alleviative treatments. The second objective was to 
determine 5-HTTLPR and SLC6A4 promoter DNA methylation status of each 
participant and calculate the allelic and genotypic frequencies and mean methylation 
levels for ASD and control cohorts, and within the ASD-trait endophenotypes.  
 
Several hypotheses are tested in this study. The main hypothesis states that there 
will be differential regulation of the SLC6A4 gene between the ASD and control 
cohorts and across the ASD endophenotypes. Secondary hypotheses are as follows: 
The genotypic and allelic frequencies of the 5-HTTLPR will differ between ASD and 
control cohorts and endophenotypes. Then, the S allele will be enriched in the ASD 
cohort and more severely affected ASD-trait endophenotypes, as studies show S 
allelic-associations to certain ASD traits (Canli and Lesch, 2007; Lin, 2007; 
McDougle et al., 1998; Sutcliffe et al., 2005; Lesch et al., 1996). Additionally, 
differential mean DNA methylation will be observed at individual CpG sites and 
across the investigated region in the ASD cohort compared to the control cohort, as 
well as between the ASD-trait endophenotypes. Finally, an interaction between the 
genotypic and allelic frequencies and promoter DNA methylation of SLC6A4 will be 
observed. 
 
These hypotheses will be tested through comparisons of the allelic and genotypic 
frequencies and mean DNA methylation levels across the two main cohorts (ASD 
and control) and the ASD endophenotypes using statistical tests.  The identification 




implicate SLC6A4 regulation within the aetiology of ASD and with ASD-trait 
development. This could allow for the determination of biomarkers within the ASD 




































Methods and Materials 
2.1. Sample cohort & phenotypic information 
A cohort of both children with ASD (n=50) and age-and gender-matched controls 
(n=13) was built for this study. At the time of this study, only 13 control participants 
were recruited based on volunteer parents, while the 50 children with ASD were 
recruited from schools and sport clubs in Cape Town, Western Cape (33.9253° S, 
18.4239° E). This included a Western Cape Government autism specialist school 
and a private autism centre. All participants were male, with an age range of 6 to 14 
years old. These parameters were chosen because of the 4 to 1 male to female 
incidence of ASD, and to avoid the confounding factor of sex-dependent changes in 
DNA methylation patterns present from birth. The study was granted both Western 
Cape Government approval (Ref: 2014002-37506) and UCT Ethics Approval 
(FSREC 076-2014); informed parental consent was obtained from all study 
participants (See Appendix for consent form). 
 
Fifty of the children were recruited from the specialist autism schools, and they all 
had a working diagnosis of ASD from the local specialist children‘s hospital, a team 
of educational psychologists and occupational therapists at the respective schools or 
a neuro-paediatrician. The entire cohort, both the children with an ASD diagnosis, 
and age-matched controls, underwent an ADOS-2 assessment (Autism Diagnostic 
Observation Schedule-2). This was conducted by a team of certified assessors, who 
were also research reliable to ensure that the ADOS scores were comparable both 
among assessors and over time. This allows for the ADOS-2 classification of autism, 
autism-spectrum and non-spectrum (control) for each child. An ADOS-2 severity 
comparison score is also assigned, classifying the participant‘s ASD as ASD-high, 
ASD-moderate or ASD-low when compared to other children with ASD of a similar 
developmental age. The ADOS-2 assessment also provides two other useful scores: 
a) SA, which is comprised of the child‘s communication and reciprocal social 
interaction, and b) RRB. These core traits are associated with ASD and used in the 




Children were excluded from the study cohort if they displayed any co-morbidity, 
such as Rett Syndrome or known chromosomal disorders (e.g. Fragile X Syndrome 
or Neurofibromatosis), or if they had a sibling already in the study. Control 
candidates were excluded if they scored above threshold on ADOS-2.  
 
Buccal cell collection and genomic DNA extraction 
DNA was obtained from buccal cells, a non-invasive method of sample collection. 
Buccal epithelial cells have the advantage of being derived from the embryonic 
ectodermal layer, the same embryonic layer from which neuronal cells are derived. 
Hence, it has been suggested that buccal cells are the ideal target tissue in neuro-
developmental studies (Olsson et al., 2010). DNA methylation patterns of epithelial 
buccal cells were also found to be more similar to those observed in brain tissue 
than observed in blood (Lowe et al., 2013).  
 
Buccal cells were collected using Catch All Sample Collection Swabs (Epicentre 
Biotechnologies, Madison, USA) from each participant over at least three separate 
occasions. Each cheek of the participants was swabbed thoroughly for 
approximately 30 seconds, with the swab placed in storage buffer comprising of 
540uL Lysis buffer (0.4M NaCl, 10mM Tris-HCl, pH 8.0, and 2mM EDTA, pH 8.0) 
and 60uL of 10 % (w/v) sodium dodecyl sulphate (1% final concentration SDS) 
immediately. The buccal cells could then be stored at 4°C for a maximum period of 
two weeks before DNA extraction. 
 
DNA was extracted from these buccal cells using the extraction protocol described in 
Aljanabi and Martinez (1997) with a few modifications. The first being the addition of 
10μL of 20 mg/mL proteinase K to the lysis buffer containing the swab, followed by 
incubation at 56°C for two hours. After incubation, 225μL of 6M saturated NaCl was 
added, followed by two rounds of centrifugation at 13,200rpm for 10 minutes on an 
Eppendorf centrifuge 5415R. The supernatant was placed into a fresh eppendorf 
after each spin. Total genomic DNA (gDNA) was precipitated by the addition of 
800uL isopropanol and incubated at -20°C overnight, followed by a 70% (v/v) ethanol 
wash step. The precipitated gDNA was resuspended in 40μL of sterile, molecular 
grade water, and stored at 4°C until use to avoid degradation by the freeze/thaw 




using the Nanodrop ND-1000 spectrophotometer (Nanodrop ® Technologies, USA). 
Quality was then confirmed by visualisation of gDNA on 0.8% (w/v) agarose gel in 
1X Tris Borate EDTA (TBA; Tris, EDTA and boric acid) buffer and stained with 
ethidium bromide.  
 
2.2. Genetic Methodology: SLC6A4 polymorphisms 
The SLC6A4 region investigated is visualised in Figure 2.1. All amplicons analysed 
are also illustrated, along with their corresponding coverage of the 5-HTTLPR and 
CpG sites.  
 
 
Figure 2.1. Representative image of the target region of the 
SLC6A4 promoter region for both the genetic and epigenetic 
analysis. The TSS is represented by a solid arrow, while the 5-HTTLPR 
is a broken arrow and upstream of these CpG sites. Each CpG site 
analysed is represented by a solid circle. CpG sites associated with 
SLC6A4 mRNA expression are coloured purple. The fragments of DNA 
amplified for the 5-HTTLPR analysis (red), bisulphite sequencing 
(yellow), native sequencing (blue) and the EpiTYPER assay (green) are 
shown along with relative coverage of the CpG sites and position to 
TSS.  
 
Repeat polymorphism & SNP rs25531 
The DNA fragment of the promoter of SLC6A4 containing the 5-HTTLPR and the 
SNP rs25531 is shown in red in Figure 2.1. This fragment was amplified under the 
following conditions: In a total volume of 25μL, 100ng of DNA were amplified in the 
presence of 2.5μL of 10× KAPA Taq buffer, 1μL of 10uM dNTP mix, 0.75μL of each 
primer and 0.2μL of 5U/μL KAPA Taq DNA polymerase (Kapa Biosystems, Boston, 
USA), with sterile, distilled water making up the reaction to 25μL. The reaction 
cycling conditions were as follows: initial denaturation at 95 °C for 3 minutes, with 35 
cycles of 95°C for 30 seconds, 65°C for 45 seconds, and 72°C for 45 seconds; 
followed by 10 minute final elongation at 72°C, using the primers described in Dukal 




using electrophoresis of the PCR product on a 2.5% (w/v) agarose gel in a 1 X TBE 
buffer stained with ethidium bromide. A 512bp amplicon was expected for the L allele 
and a 469bp amplicon for the S allele.  
 
The SNP, rs25531, on the L allele of 5-HTTLPR, was then determined through 
restriction fragment length polymorphism (RFLP) analysis by digesting 20μL of the 
PCR product with HpaII (New England Biolabs) per manufacturer‘s instructions. This 
allows for the detection of the rare G allele of rs25531, as the DNA sequence, 5‘ – 
CCAG – 3’, would be altered to the restriction recognition site, 5‘ – CCGG – 3’. The 
status of rs25531 was resolved on a 2.5% (w/v) agarose gel in a 1 X TBE buffer 
stained with ethidium bromide. The LA and S alleles were expected to remain uncut, 
while the LG allele was expected to show amplicons of 402bp and 110bp in length.  
 
2.3. Epigenetic Methodology: DNA Methylation  
The DNA methylation analysis was completed in two ways, first qualitatively and the 
second, quantitatively. Both methods involve sodium bisulphite treatment of the 
DNA. When treated with sodium bisulphite, any unmethylated cytosines are 
converted to uracil residues, while methylated sites would be protected and remain 
as cytosines. The qualitative method involves bisulphite sequencing, developed by 
Frommer et al. (1992) and allows for the detection of methylation-dependent 
sequence variations. Primers are altered to match the converted DNA. A native 
fragment (unconverted DNA) of the target region is also sequenced in order to 
identify potential SNPs which may account for any variations that could create or 
destroy a CpG site.  The second method involves the use of the EpiTYPER assay, 
conducted on the Sequenom MassARRAY system (Agena Bioscience, San Diego, 
CA). EpiTYPER is a mass spectrometry bisulphite sequencing method. It allows for 
quantitative measurement of DNA methylation levels at a single-nucleotide resolution 
(Suchiman et al., 2015). This was also completed, because the qualitative 
methodology was not sufficient to detect low levels of DNA methylation. 
 
2.3.1. Qualitative analysis 
Bisulphite converted DNA sequencing  
In order to analyse CpG methylation status, gDNA was treated with sodium 




(Zymo Research, Orange, CA, USA). The converted DNA quantity was then 
assessed using the Nanodrop ND-1000 spectrophotometer (Nanodrop ® 
Technologies, USA), using the single stranded DNA setting due to the converted 
nature of the DNA.  
 
A 201bp region, covering the seven CpG sites associated with mRNA expression of 
SLC6A4, and shown in yellow in Figure 2.1, was amplified. In a total volume of 25μL, 
100ng of DNA were amplified in the presence of 5μL of 5× KAPA Taq HotStart 
buffer, 1μL of 10uM dNTP mix, 1μL of each primer and 0.2μL of 5U/μL KAPA Taq 
HotStart DNA polymerase, with sterile, distilled water making up the reaction to 
25μL. The reaction cycling conditions were as follows: initial denaturation at 95 °C for 
15 minutes; with 40 cycles of 95°C for 15 seconds, 57°C for 30 seconds, and 72°C 
for 15 seconds; followed by 5 minute final elongation at 72 °C. Primers described by 
Kim et al. (2013) were used in the amplification, altered according to the converted 
DNA sequence (See Appendix Table A). Amplification confirmation was completed 
using gel electrophoresis by running 5uL of the product on a 1.5 % (w/v) agarose gel 
in a 1 X TBE buffer stained with ethidium bromide. The converted PCR product was 
then purified from the agarose gel using the ZymocleanTM Gel DNA Recovery Kit 
(Zymo Research, Orange, CA, USA), and sent to the Centre for Analytical Services 
(CAF) at the University of Stellenbosch (Stellenbosch, Western Cape, South Africa) 
for BigDye sequencing on the BigDye Terminator V3.1 sequencing kit (Applied 
Biosystems) with only slight modifications to the manufacturers‘ protocol. CAF 
utilises the ABI 3730xl to run the amplicons, as well as the AB Foundation DATA 
Collection v3.0 and Sequence Analysis v5.3 to complete the data collection and 
perform sequence analysis. The chromatograms were visualised and edited using 
Chromas software (downloaded from http://technelysium.com.au/wp/chromas on 11 
September 2015, (Technelysium Pty Ltd, Tewantin QLD, Australia). 
 
Native DNA Sequencing 
A 444bp target region, containing the CpG sites to be investigated, was amplified 
using a high-fidelity DNA polymerase in order to sequence the native DNA. This 
allows for sequence comparison to bisulphite treated DNA. The intended target 
region is shown in blue in Figure 2.1. In a total volume of 20μL, 20ng of DNA was 




1μL of each primer and 0.2μL of Phusion DNA polymerase (Thermo Scientific, 
Vilnius, Lithuania), with sterile, distilled water making up the reaction to 20μL. The 
two-step reaction cycling conditions were as follows: initial denaturation at 98 °C for 
30 sec, with 35 cycles of 98 °C for 10 sec and 72°C for 35 sec; followed by 10 min 
final elongation at 72 °C. The forward primer 5‘ – GCCGGTCAGTCAGATAAACG – 3‘ and reverse 
primer 5‘ – CGTCACTTTGAGGCGAATAAA – 3‘ used were designed in Primer3Plus Design 
(Untergasser et al., 2012; See Appendix Table A). Confirmation of amplification was 
completed using gel electrophoresis by resolving 5μL of the product on a 1.5 % (w/v) 
agarose gel in a 1 X TBE buffer stained with ethidium bromide.  
 
The remaining PCR product underwent electrophoresis on a 0.8% (w/v) agarose gel 
in a 1 X TBE buffer stained with ethidium bromide, in order for the product at the 
444bp region to be cut out. The DNA was then extracted from these gel slices using 
the ZymocleanTM Gel DNA Recovery Kit (Zymo Research, Orange, CA, USA). The 
gel extracted amplicons were sent for BigDye sequencing, as described above for 
the converted DNA. The sequences were aligned using Molecular Evolutionary 
Genetics Analysis (MEGA) software (downloaded from http://www.megasoftware.net 
on 15 September 2015; Stecher et al., 2013), in order to identify any SNPs that may 
alter the sequence. Potential transcription factor binding sites that may overlap with 




2.3.2. Quantitative analysis 
EpiTYPER MassARRAY Methylation Assay 
The EpiTYPER assay involves the examination of PCR-amplified converted DNA 
with a mass spectrometer. The basic steps involve treating genomic DNA with 
sodium bisulphite, amplifying the converted DNA with primers tagged with a T7 
promoter and treating this with shrimp alkaline phosphatase (SAP). RNase A 
cleavage follows along with transcription of the amplicon into single RNA strands 
with the T7 promoter. A final cleaning step involves resin and the samples are then 
loaded onto a SpectroCHIP R II Array, preparing the samples for separation with the 
mass spectrometer. The mass spectrometer is a MALDI-TOF device and makes use 




increases with the 16 Da higher mass of a methylated CpG site compared to an 
unmethylated one.  The size of the two peaks can be used in the calculation of the 
methylation ratio of each target CpG site. Detection of certain CpG sites is limited 
when fragments of the target region are too similar in mass to another fragment. The 
final result is given as a DNA methylation percentage of each CpG site (Suchiman et 
al., 2015).  
 
The EpiTYPER assay was conducted on the Sequenom MassARRAY system 
(Agena Bioscience, San Diego, CA) at Inqaba Biotec (Pretoria, South Africa). 
Genomic DNA was treated with sodium bisulphite using the EZ DNA Methylation Kit 
(Zymo Research, Orange, CA, USA) as per manufacturer‘s instructions. The gDNA 
quantity and quality was assessed using the Nanodrop ND-1000 spectrophotometer 
(Nanodrop ® Technologies, USA) prior to conversion, while the post-treatment 
analysis was completed at Inqaba using Picogreen RNA settings (PicoGreen®).  
 
A 467bp region of the 5-HTT promoter was amplified using bisulphite-conversion 
based PCR primers, designed in EpiDesigner Beta (www.epidesigner.com): 5‘–
TTGTTAGGTTTTAGGAAGAAAGAGAGA–3‘ and 5‘– CCCTCACATAATCTAATCTCTAAATAACC – 3‘ (See Appendix 
Table A). This region is shown in green in Figure 2.1, and covers 21 of the 40 CpG 
sites for the massARRAY purposes. This is because certain fragments are too 
similar in mass. In a total volume of 9μL, 1μL of 10ng/μL (10ng) of DNA was 
amplified in the presence of 1μL of 10× PCR buffer with 20mM MgCl2, 0.08μL of 
25mM dNTP mix, 2μL of each primer, 0.08μL of PCR Enzyme (5U/μL) and 2.84μL 
sterile, distilled water. The specific PCR enzyme and buffer makeup is copyrighted to 
the assay and service provider. Amplification was performed at the following cycling 
conditions: initial denaturation at 94°C for 4 minutes, 45 cycles of 94°C for 20 
seconds, 56°C for 30 seconds and 72°C for 1 minute; followed by the final extension 
for 3 minutes at 72°C. This was also completed for a negative control sample 
(without bisulphite-treated DNA), as well as controlled methylated DNA at levels of 
0%, 25%, 75% and 100%. A T7 promoter-tagged reverse primer was used to allow 
for in vitro transcription at a later stage.   
 
The manufacturer‘s instructions were followed for the remainder of the EpiTYPER 




dNTPs in the reaction, which was incubated at 37°C for 20 minutes and 85°C for 5 
minutes. Following this, the in vitro RNA transcription with subsequent T (U)-specific 
cleavage using RNase A was completed to yield fragmented RNA molecules, 
through incubation of 37°C carried out for 3 hours. Both methylated and non-
methylated regions are cleaved on the reverse strand only, allowing equal length 
fragments which differ only in the nucleotide composition.  
 
The products were then conditioned for the MALDI-TOF mass spectrometer using 
Clean Resin, optimising mass spectrometry analysis and transferred to a 
SpectroCHIP array using the MassARRAY nanodispenser, whereby the different 
signals generated by the mass difference between the non-methylated and 
methylation fragments were recorded. In this assay, the mass difference detected by 
the MassARRAY system would result from guanine/adenine changes rather than 
cytosine/thymine changes due to the use of the reverse strand. The Analyser 
program of EpiTYPER 1.2 (Agena Bioscience, San Diego, CA) was used to display 
the spectra and produce the quantitative methylation results, which included 
percentage methylation per CpG site of the whole tissue type.  
 
2.4. Statistical Analysis 
Hardy-Weinberg exact tests were used to determine whether the 5-HTTLPR L and S 
allelic frequencies were in Hardy Weinberg equilibrium (HWE) (Simple Hardy-
Weinberg Calculator - Court Lab). All remaining statistical analyses were completed 
using IBM SPSS Statistics 22 (IBM Corp. Released 2013. IBM SPSS Statistics for 
Windows, Version 22.0. Armonk, NY: IBM Corp), with statistical significance 
accepted at p<0.05. Genotypic and allelic frequency distributions for comparisons 
across the phenotypic grouping were completed using the two-tailed Fisher‘s exact 
test, due to the small sample sizes of the ASD endophenotypes. Odds ratios and 
relative risk associations were completed for the ASD and control cohort comparison 
to determine the 5-HTTLPR allele risk. The Mann-Whitney U test was used to 
compare the quantitative DNA methylation results, both median and spread of data, 
across the comparison groups, due to the non-normal distribution of DNA 
methylation data and the sample size constraints (Hart, 2001). The quantitative data 
were reported as the mean methylation percentage per site or region ± standard 






3.1. Cohort and ASD endophenotypes 
ADOS-2 assessments provided detailed, standardised phenotypic information for 
sixty three individuals. Using the exclusion criteria and ADOS-2 assessments, 25 of 
the children diagnosed with ASD and 7 of the control participants did not meet the 
requirements, highlighting the value of completing an ADOS-2 assessment on both 
cohorts. The resultant, clearly phenotyped group included participants with ASD 
(n=25) and age-matched controls (n=6). A summary of the ages and ancestry of the 
final cohorts are shown in Appendix Table B. The participants were from varied 
ancestral backgrounds and the mixed ancestry (an admixed population group 
including African, European and Asian ancestry) and African ancestry groups were 
combined for statistical analysis purposes due to the small sample size (n=3) of the 
African group.  
 
The ADOS-2 assessment was used to reduce the phenotypic heterogeneity of the 
ASD cohort. The ASD cohort was sub-grouped using the ADOS-2 severity 
comparison scores, the SA scores and the RRB scores. The SA score is comprised 
of social communication and reciprocal social scores.  The choice of which ADOS-2 
module to administer is based on the level of expressive language of the participant. 
Module 1 was used when the participant was pre-verbal or used single words only, 
while module 2 was used for participants who used phrase speech. Module 3 was 
used for participants with fluent language, as well as for the entire control cohort. 
The ADOS-2 module was also used as one of the ways to create ASD language 
endophenotypes. The resultant ASD endophenotypes used in this study are 
summarised in Table 3.1. These endophenotypes represent smaller subgroups of 
the ASD cohort according to specific ASD-traits, thereby reducing the phenotypic 







Table 3.1. Endophenotypes of the ASD cohort and control cohort using criteria based on 
ADOS-2 
Phenotypic groups and ASD-trait 
Endophenotypes 
ADOS-2 criteria Sample Size (n) 
ASD ASD on ADOS-2 25 
Control No score on ADOS-2 6 
ASD-High Comparison score ≥ 8 5 
ASD-Moderate Comparison score 5 ≥ n < 8 20 
Pre-verbal/Single words Module 1 completed 14 
Phrase Speech Module 2 completed 8 
Fluent Language Module 3 completed 3 
High SA ADOS-2 SA score ≥ 8 23 
Low SA AODS-2 SA score < 8 2 
High RRB ADOS-2 RRB score ≥ 6 6 
Low RRB ADOS-2 RRB score < 6 19 
ASD-Autism spectrum disorder; SA-Social affect; RRB-Repetitive and restricted behaviour; with high and low 
referring to the level of severity of ASD and ASD-traits. 
 
The endophenotypes listed in Table 3.1 were used in all subsequent genotype-
phenotype association analyses. The genotypic and allelic frequencies of the 5-
HTTLPR and SLC6A4 DNA methylation levels were compared across all the ASD 
endophenotypes using the two tailed Fisher‘s exact test and Mann-U Whitney test, 
respectively. This was completed to identify any associations between the S or L 
alleles of the 5-HTTLPR, and levels of SLC6A4 promoter DNA methylation, with ASD 
or specific ASD-traits. Pairwise comparisons were done between the control 
participants and entire ASD cohort, as well as between the control cohort and 
various ASD endophenotypes. These ASD endophenotypes are ASD-high, ASD-
moderate, high SA, high RRB, pre-verbal and phrase speech. The high RRB 
endophenotype was also compared to the low-RRB endophenotype. Only two ASD 
participants had low SA scores and three had fluent language, therefore these two 
endophenotypes were not used in the pairwise comparisons. The detailed results of 








3.2. Repeat polymorphism and SNP rs25331 
The 5-HTTLPR and rs25531 SNP in the promoter region of SLC6A4 were genotyped 
using RFLP for twenty four of the ASD participants, while all six participants of the 
control cohort were genotyped. Only twenty four of the twenty five ASD participants 
were used for RFLP due to shortage of DNA. The genotypic and allelic frequency 
distributions were calculated. Tests for deviation from HWE were performed for the 
genotype frequencies at the 5-HTTLPR locus and there was no significant deviation 
from HWE. This test was completed for the entire cohort, as well for ASD and control 
cohorts separately (p=0.18, 0.09 and 0.62, respectively). 
 
Repeat polymorphism and SNP rs25531in the ASD and control cohorts  
In the ASD cohort, five of the participants were LL homozygous (20.8%); sixteen 
were LS heterozygous (66.7%), and three were SS homozygous (12.5%). In the 
control cohort, two of the participants were LS heterozygous (33.3%), while the 
remaining four control participants were LL homozygous (66.7%). The SS 
homozygous participants were combined with the LS heterozygous participants to 
calculate a frequency distribution representing genotypes associated with lowered 
SLC6A4 expression, since the S allele is thought to act in a dominant manner (Hu et 
al., 2006). These are the ‗low expression‖ individuals, while the LL participants are 
considered the ―high expression‖ individuals. When the rs25531 SNP is taken into 
account, any LL participants with at least one G variant of the SNP at the SLC6A4 
promoter are added to the ―low expression‖ group. None of the LL participants in the 
ASD cohort contained the G variant, while one of the control LL participants had the 
rs25531 SNP and was thus added to the ―low expression‖ SLC6A4 group in the 
analysis. The L/S allelic frequencies and genotypic frequency distributions are shown 










Figure 3.1. Frequency distributions for the 5-HTTLPR genotypes 
(A) and rs25531genotype modified-expression (B) of participants in 
the ASD (n=24) and control cohorts (n=6). LL, LS and SS represent 
the three 5-HTTLPR genotypes, while High and Low represent high 
expression and low expression of SLC6A4, taking the effect of rs25531 
into account. These were compared between the ASD cohort (n=24) 
and control cohort (n=6) using the two-tailed Fisher‘s exact test. 
Significance is denoted by * (p<0.05).   
 
 
The genotypic frequency distribution based on the 5-HTTLPR genotypes, where any 
S allele containing genotypes were combined, was found to be significantly different 
between the ASD cohort and the control cohort (p=0.049, refer to Figure 3.1). An 
enrichment of the S allele-containing genotypes in the ASD cohort is observed, with 
a 2.38-fold increase in the frequency of these genotypes (79.2%) compared to the 
control cohort (33.30%). However, the presence of the rs25531 G variant for one of 
the LL control participants increased the frequency within the ―low expression‖ group. 
The adjusted frequency distribution based on the incorporation of the rs25531 SNP 
into the calculations was not found to be significantly different between the ASD and 
control cohorts (p=0.3), with only a 1.58-fold increase in ―low expresser‖ frequency 
observed (79.2% for the ASD cohort and 50% for the control cohort). 
 
The significant difference in the genotypic frequency distribution is supported by the 
odds ratio/relative risk data. The relative risk assessment revealed that the presence 
of the L allele significantly decreases the risk for ASD to a relative risk of 0.78. (95% 



























































3.20-fold increase of the LL genotype (Figure 3.1) in the control population compared 
to the ASD cohort. The relative risk is based on the allelic distribution, however it is 
must be noted that the allelic frequency distribution was not found to be significantly 
different between the two cohorts using the two-tailed Fisher‘s exact test (p=0.1), as 
seen in Figure 3.2. Although, a 1.5-fold increase in the L allele in the control cohort 
does correspond to a 2.7-fold decrease of the S allele compared to the ASD cohort, 
showing an observed enrichment of the S allele in the ASD population compared to 
the control cohort.  
 
 
Figure 3.2. Frequency distribution for the 5-HTTLPR L and S alleles 
in the ASD (n=24) and control cohorts (n=6). The allelic frequencies 
were compared between the two cohorts using the two-tailed Fisher‘s 
exact test (Significance set at p<0.05).  
 
 
Repeat polymorphism and SNP rs25531in the ASD endophenotypes 
Both genotypic frequency distributions and the allelic frequencies were also 
calculated for the all endophenotypes listed in Table 3.1 and then used in the 
aforementioned comparisons using the two-tailed Fisher‘s exact test (See Appendix 
Table C). However, none of these comparisons yielded any significant results, with 
only the more severely affected ASD endophenotype, ASD-high, approaching the 
































p=0.061) when compared to the control cohort. The comparison of the frequency 
distributions between participants of different ancestry (African/mixed ancestry and 
European ancestry) also did not yield any significant differences (p=0.226). 
 
In summary, the presence of the L allele appears to significantly reduce the risk of 
developing ASD. This is supported by both the genotypic comparison of the LL vs. 
LS/SS in an ASD cohort to a control cohort and the relative risk result. A significant 
enrichment of S-allele containing genotypes as well as a 2.7-fold increase of the S 
allele is also observed in the ASD cohort.  
 
3.3. SLC6A4 Promoter DNA Methylation 
The native (or not converted) sequences for both the ASD and control cohorts were 
aligned using the multiple sequence alignment tools in MEGA (See Appendix Figure 
A). This allowed for the identification of SNPs in both cohorts‘ native DNA 
sequences. No SNPs were found to overlap with any of the CpG sites. Only two of 
the participants contained a single sequence variant and were heterozygous for a T - 
C SNP, rs25533. This SNP was identified in one individual with ASD and one control 
participant. 
  
Using the native SLC6A4 promoter sequence as a reference, Alibaba 2.1 predicted 
potential DNA regions that five transcription factors could potentially bind. There are 
15 potential binding sites for these transcription factors in this region covering all but 
two of the CpG sites. These transcription factors are the: specificity protein 1 (SP1), 
activating enhancer binding Protein 2 alpha (AP2-alpha), protein c-ets-1 (C-Ets-1), 
nuclear factor 1 (NF-1) and Represso. The recognition site for Sp1 is 5'-GGGCGG-3' 
(Giallongo et al., 1990); AP2-alpha is 5‘-GCCNNNGGC-3‘ (Williams and Tjian, 
1991); NF-1 5'-TTGGCNNNNNGCCAA-3' (De vries et al., 1987), while C-Ets-1 has a 
5‘-GGAA/T-3‘ core element (Wotton et al., 1994). Figure 3.3 maps these sites along 










Figure 3.3.Representative image of the target region with the 
position of each CpG site analysed using the EpiTYPER assay. The 
Transcription Start Site (TSS) of the SLC6A4 gene is included, along 
with any transcription factor binding sites which may overlap the CpG 
sites. The five transcription factors that bind to these putative sites are 
Sp1, AP2-alpha, C-Ets-1, NF-1 and Represso. Only CpG 3 and CpG 37 
do not overlap with a putative binding site.  
 
 
DNA sequences were produced for the bisulphite converted DNA of all 31 
participants. The chromatograms of the converted sequences were analysed using 
Chromas 2.4. Visual inspection of the chromatograms allows for the analysis of 
individual peaks at each nucleotide position of the region investigated. Any 
remaining methylated cytosine residues would be observed as cytosine peaks, while 
the unmethylated cytosines would now be thymine peaks. DNA methylation was not 
evident from the sequence results; there were no clear cytosine peaks observed. On 
closer inspection, only one site (CpG 4) showed a small peak representative of a 
conserved cytosine residue. However, as seen in the chromatogram (Appendix 
Figure B), any background noise renders an unequivocal identification of DNA 
methylation presence unlikely. The results from bisulphite sequencing suggest very 
low levels of DNA methylation for the SLC6A4 promoter region; therefore a more 
sensitive assay of methylation, the EpiTYPER, was used.  
 
Using the EpiTYPER assay, DNA methylation levels of the SLC6A4 promoter were 
obtained for all 25 of the ASD participants and six of the controls. Twenty one of the 
potential 40 CpG sites in the region investigated were covered by the EpiTYPER 
assay. The final results include data from 12 CpG regions covering these 21 CpG 
sites, illustrated in Figure 3.4. Certain CpG sites that are closely situated were 




manually combined for data analysis, because identical levels of DNA methylation 
for these sites were observed for each participant.   
 
SLC6A4 Promoter DNA Methylation in the ASD and control cohorts 
The overall DNA methylation level for the entire region investigated was calculated 
using the individual CpG site DNA methylation levels. Both the average individual 
CpG site DNA methylation and the average DNA methylation across all CpG sites 
are shown in Figure 3.4. The technical controls of 0%, 25%, 75% and 100% 
methylated DNA are shown in Appendix Figure C.  
 
 
Figure 3.4. Average DNA methylation of the SLC6A4 promoter for 
each target CpG site and DNA methylation across the 12 CpG 
regions in both the ASD (n=25) and control cohorts (n=6). The DNA 
methylation levels of the different cohorts were compared using the 
Mann-U Whitney test. Significance is denoted by * (p<0.05).  
 
  
The target promoter region of the SLC6A4 gene is located between 102bp and 
506bp upstream of the gene (Figure 3.3) and showed low levels of DNA methylation. 
The methylation levels range from 0% to a maximum of 15% (CpG 11) for a control 
participant and 14% (CpG 30) for a participant with ASD. Methylation levels varied 




























regions (%±SD) was significantly higher (p=0.011) in the control cohort (3.10±1.15%) 
compared to the ASD cohort (1.99±0.88%), as shown in Figure 3.4. However, 
differences in the levels of individual CpG site DNA methylation between the ASD 
and control cohorts were not significant.  
 
Closer examination of the DNA methylation levels revealed variability in percentage 
across all sites, ranging from 0.39±1.16% (CpG 31/32) to 5.34±5.10% (CpG 11). 
However, the EpiTYPER assay results of 14.17% for the 25% technical control, 
53.58% for the 75% technical control and 91.5% for the 100% technical control 
report an underrepresentation of the DNA methylation percentages.   
 
SLC6A4 Promoter DNA Methylation in the ASD endophenotypes  
The DNA methylation levels for these CpG sites were then compared across the 
ASD endophenotypes and the significant differences for both average and individual 
CpG site DNA methylation are shown in the figures below. First, the ADOS-2 
comparison score-generated endophenotypes of ASD-high and ASD-moderate were 
compared to the control cohort. Average DNA methylation of the control cohort 
(3.10±1.15%) was significantly higher (p=0.004) than that observed for the ASD-
moderate endophenotype (1.87±0.77%), as seen in Figure 3.5. However, the 
average DNA methylation of the control cohort was not significantly higher than that 
observed for the ASD-high endophenotype (2.50±1.19%, n=5, p=0.457). The other 
non-significant comparisons, including the ASD-high versus control comparison, are 








Figure 3.5. Average DNA methylation across all 12 target CpG 
regions of the SLC6A4 promoter for the control cohort (n=6) and 
the ASD-moderate endophenotype (n=20). The DNA methylation 
level of the ASD-moderate endophenotype was compared to the control 
cohort using the Mann-U Whitney test. Significance is denoted by * 
(p<0.05).   
 
 
When using language impairment as a way to partition the ASD cohort and then 
compare to the control, differences in DNA methylation levels were observed (Figure 
3.6). Significance was observed across the CpG sites, but not at specific CpG sites 
(Appendix Table D). The control cohort displayed significantly higher average DNA 
methylation across the CpG sites (3.10±1.15%) compared to the participants who 
are pre-verbal (1.81±0.51%, p=0.004), used phrase speech only (1.83±1.04%, 
p=0.026) and the combined pre-verbal/phrase speech endophenotype (1.81±0.72%, 
p=0.003). No significant difference was observed between the participants who are 



































Figure 3.6. Average DNA methylation across all 12 target CpG 
regions of the SLC6A4 promoter for the control cohort (n=6), the 
pre-verbal endophenotype (n=14), phrase speech endophenotype 
(n=8) and the combined pre-verbal/phrase speech endophenotype 
(n=22). The DNA methylation level of the three endophenotypes was 
compared to the control cohort using the Mann-U Whitney test. 
Significance is denoted by * (p<0.05).   
 
 
The comparisons of DNA methylation based on ASD-trait severity, specifically for SA 
and RRB against the control cohort also yielded significant results. These data are 
presented in Figure 3.7. Both endophenotypes displayed significant differential DNA 
methylation across the CpG sites. Figure 3.7 shows that participants with more 
severe SA symptoms showed significantly decreased DNA methylation levels 
(p=0.006) across the CpG sites (1.90±0.88%) compared to the average DNA 
methylation level of the control cohort (3.10±1.15%). The control cohort also 
displayed significantly increased DNA methylation (p=0.045) compared to the high 
RRB endophenotype (1.95±0.58%).  The remaining comparison results for individual 







































Figure 3.7. Average DNA methylation across all 12 target CpG 
regions of the SLC6A4 promoter for the high SA endophenotype 
(n=23), the high RRB endophenotype (n=6) and the control cohort 
(n=6). The DNA methylation levels of the two endophenotypes were 
compared to the control cohort using the Mann-U Whitney test. 
Significance is denoted by * (p<0.05).     
 
 
When compared to the control cohort, differential DNA methylation was also 
observed at the CpG 1 site in the high RRB endophenotype. At this site of the 
SLC6A4 promoter region, significantly increased methylation (p=0.045) was 
observed in the control cohort (3±1.22%) compared to the high RRB endophenotype 



































Figure 3.8. Average DNA methylation for the CpG 1 site of the 
SLC6A4 promoter for the control cohort (n=6) and High RRB 
endophenotype (n=6). DNA methylation levels of the two groups were 
compared using the Mann-U Whitney test. Significance is denoted by * 
(p<0.05).   
 
 
However, when the high RRB endophenotype was compared to the low RRB 
endophenotype, average DNA methylation levels at the CpG 30 site were found to 
be significantly increased (p=0.001) in the more affected (high) RRB endophenotype 
(3.00±1.22%) compared to the less affected RRB endophenotype (1.17±3.37%), 
observed in Figure 3.9. This is the only significant result of an endophenotype or 
subgroup of ASD that shows increased methylation with an increase in severity of 
symptoms or ASD. The control cohort and therefore less severe ASD traits have 

































   
Figure 3.9. Average DNA methylation for CpG 30 of the SLC6A4 
promoter for the high RRB endophenotype (n=6) and the low RRB 
endophenotype (n=25). The DNA methylation level of the two 
endophenotypes was compared using the Mann-U Whitney test. 
Significance is denoted by * (p<0.05).   
 
 
In an attempt to identify any association between the levels of DNA methylation at 
the SLC6A4 promoter and the 5-HTTLPR, the methylation levels of the 5-HTTLPR 
groupings were compared. No significant average DNA methylation differences 
across all 12 CpG regions were observed between the LL participants and the LS/SS 
participants (p=0.445) or between the high and low SLC6A4 expressers (p=0.557).   
 
DNA methylation at the SLC6A4 promoter was also compared across the different 
ancestry groups and according to age to account for any ancestry-or age-dependent 
changes to the DNA methylation. Average DNA methylation across all 12 CpG 
regions was not found to be significantly different in the two ancestry groups 
(p=0.080, see Appendix Table D). Only CpG24/25 showed significantly increased 
methylation (p=0.008), in participants of European ancestry (4.00±0.91%) compared 
to those of African ancestry (2.50±0.97%, see Appendix Figure D).  No significant 
age-differences in average DNA methylation across all12 CpG regions (p=0.358) 



































Serotonergic signalling and serotonin levels have long been associated with the 
aetiology of ASD (McDougle et al., 1996; Makkonen et al., 2008; Murphy et al., 2006; 
Huang et al., 2008; Guhathakurta et al., 2009; Hranilovic et al., 2010; Kistner-Griffin 
et al., 2011). The most promising, yet ambiguous evidence, of this association is the 
presence of hyperserotonemia in up to 35% of ASD cases (Hranilovic et al., 2007). 
One of the potential disruptions to serotonergic signalling involves altered regulation 
of the serotonin transporter and therefore impaired reuptake of serotonin (Heils et al., 
1996; Lesch et al., 1996). Changes in regulation of this transporter often attributed to 
the well-studied repeat polymorphism (5-HTTLPR) have proven to be inconclusive 
(Canli and Lesch, 2007; Lesch et al., 1996; Kistner-Griffin et al., 2011; Arieff et al., 
2010; Cho et al., 2007; Yirmiya et al., 2001; Ma et al., 2010; Persico et al., 2002; 
Ramoz et al., 2006). However, recent evidence has emerged suggesting a stronger 
role of environmental factors working via epigenetic mechanisms, such as DNA 
methylation, in ASD aetiology (Wong et al., 2014; Melnyk et al., 2012; Nguyen et al, 
2010). Furthermore, literature suggests that a potential interplay between the repeat 
polymorphism and DNA methylation at the SLC6A4 promoter may be involved in 
conferring susceptibility to ASD (Philibert et al., 2007; van Ijzendoorn et al., 2010; 
Vijayendran et al., 2012). Both the repeat polymorphism and SLC6A4 promoter DNA 
methylation were investigated in this study. 
 
This study tested the hypothesis that the regulation of the serotonin transporter is 
different between an ASD and a control cohort, as well as between certain 
endophenotypes of ASD. Both regulatory mechanisms, the 5-HTTLPR and DNA 
methylation data presented here, support the involvement of serotonergic signalling 
within ASD aetiology. This is true for both ASD as a whole, as well as for certain 
traits associated with ASD, such as language impairments, SA and RRB. 
Furthermore, the importance of serotonergic signalling pathways in ASD is 
supported by significant differences in the 5-HTTLPR genotypic variant distributions 




DNA methylation patterns are also observed in the same ASD cohort and across 
ASD endophenotypes. 
 
4.1. Reducing phenotypic heterogeneity 
In order to effectively reduce the phenotypic heterogeneity that confounds many 
studies on ASD, smaller, homogenous endophenotypes were created. All 
participants, including the control cohort, underwent an ADOS-2 assessment to be 
placed into particular ASD endophenotypes. The endophenotypes created from the 
ADOS-2 assessments included varying ASD trait groups. This includes subgroups 
with varying language ability and subgroups based on severity of SA behaviours and 
the severity of RRB symptoms (Table 3.1). These endophenotypes are 
representative of the core domain limitations that characterise ASD in both the 
previous DSM-IV and current, revised DSM-V (APA, 2013). 
 
To empirically explore a number of traits or categories of ASD, nine endophenotypes 
were created. The smallest grouping classified according to the ADOS-2 comparison 
scores was the ASD-high subgroup. This subgroup included five participants. 
However, this represents a clean, well-defined subgroup of ASD and therefore was 
still used in comparisons. The ASD-high subgroup refers to individuals with severe 
core ASD domain impairments compared to other children with ASD of similar 
developmental ages, and therefore could potentially show the biggest difference in 
regulation of the serotonin transporter gene compared to a control cohort.  
 
Additionally, it is important to note that the entire ASD cohort is also representative of 
a clean ASD phenotype because of the strict exclusion criteria. Indeed, a number of 
potential participants with ASD were excluded from the study through a number of 
criteria. These criteria included another diagnosis, confirmed or suspected, of other 
chromosomal disorders, if the participant already had a sibling in this study, to 
exclude familial genetic associations, or if participants did not score on the ADOS-2 
in spite of an ASD diagnosis. Noteworthy, any control participants were excluded if 
they scored on ADOS-2 or displayed severe speech delay. The latter highlights the 
value of excluding control participants who may have ―ASD-like‖ traits and to ensure 
that all the behaviours used to characterise ASD are indeed qualitative traits. The 




with reduced phenotypic heterogeneity. The molecular regulation of the serotonin 
transporter was then compared across these more homogenous endophenotypes. 
However, any significant change in SLC6A4 regulation that may result from ancestry 
or age was first determined.  
 
Notably, the 5-HTTLPR genotypic and allelic frequency distributions or DNA 
methylation levels did not significantly change across the ancestry groups or 
according to age (See Appendix Tables C and D); with the exception of the CpG 
24/25 site (Appendix Figure D). This supported the comparisons of the control 
cohort, comprised of participants from European ancestry only. However, due to 
sample size constraints of the cohort, the effects of ancestry could not be rigorously 
tested.  The clear limitation of sample size also partially extends to the 
endophenotypes. It is compounded by the fact that only a fraction of the starting 
sample cohort was used in the final analysis of this study. This is the result of the 
strict exclusion criteria and ADOS-2 thresholds required for the building of a clean 
ASD and control phenotype, as well as clean endophenotypes.  The cohort building 
is a time consuming, arduous task, especially so in a South African context, where 
no established ASD databank exists. This is in contrast for other studies where, for 
example in the United States, there is access to AGRE (Autism Genetic Research 
Exchange, USA) or Simons Simplex Collection (SSC), a resource of the Simons 
Foundation Autism Research Initiative (SFARI). However, even with a relatively 
small sample size, significant data for both the 5-HTTLPR and SLC6A4 DNA 
methylation were obtained. This indicates the potential utility of this region for further 
analyses with even larger sample sizes to validate these findings, as well as to 
identify further significant links to endophenotypes. 
 
4.2. Repeat polymorphism in the ASD and control cohorts   
Due to the long-standing association of ASD and ASD-traits with the serotonin 
transporter repeat polymorphism (Canli and Lesch, 2007; Lesch et al., 1996; Lin, 
2007; McDougle et al., 1998; Sutcliffe et al., 2005; Kistner-Griffin et al., 2011; Arieff 
et al., 2010; Cho et al., 2007; Yirmiya et al., 2001), it was hypothesised in this study 
that there would be differential genotypic and allelic frequency distributions of the 5-
HTTLPR in the ASD cohort, as well as across ASD-trait endophenotypes. This 




polymorphism revealed that the presence of the L allele in a population significantly 
reduces the risk of ASD (RR=0.78; 95%, confidence interval: 0.622-0.997). In 
addition, a significantly increased presence of S allele-containing genotypes was 
observed in the ASD cohort compared to the control (Figure 3.1A, p=0.049). This 
enrichment of the S allele within an ASD population supports the study hypothesis of 
an increase in the S allele in the ASD cohort. This suggests that impaired serotonin 
transporter function may be implicated in ASD aetiology. Furthermore, this is 
supported by previous literature implicating the short allele in ASD development 
(Kistner-Griffin et al., 2011). These authors reported over-transmission of the S allele 
of the 5-HTTLPR in an AGRE sample cohort. The S-allele containing genotypic 
enrichment in this South African ASD population could potentially result in lowered 
SLC6A4 mRNA transcription and therefore disruption to the serotonin transporter 
function and serotonergic system. 
 
The 5-HTTLPR L allele is generally associated with higher levels of serotonin 
transporter mRNA transcription, as well as an increased level of serotonin reuptake 
(Heils et al., 1996; Lesch et al., 1996). Therefore, participants homozygous for the S 
allele would potentially have reduced reuptake of serotonin. This could result in the 
hyperserotonemia observed at higher frequencies in ASD individuals. The LS 
heterozygous genotype acts similarly to the SS homozygous genotype, because of 
the dominant effect of the S allele of the 5-HTTLPR (Hu et al., 2006). Therefore, the 
significant increase in LS/SS genotypes in the ASD cohort may contribute to ASD 
aetiology by impacting upon the serotonin reuptake mechanism. However, when the 
effect of the rs25531 SNP of the L allele is incorporated into the genotypic frequency 
calculations, the significance of this association is lost (Figure 3.2, p=0.3). The 
genotypic frequency distribution changes as the LG allele would now be grouped 
similarly to the S allele. The loss of significance may be due to the presence of the G 
variant in only two LS heterozygous ASD participants. This LGS genotype would 
remain in the ―low expression‖ group and did therefore not affect the genotypic 
frequency calculations of the ASD cohort. The genotypic frequency calculations are 
only changed with the presence of the G variant on the L allele of LL homozygous 
participants, as observed in one control participant. Therefore, the control population 




this cohort. However, the genotypic frequencies vary across other populations as 
well (Esau et al., 2008; and references within).  
 
Due to the variation across populations, the data in this study were compared to 
previous results obtained within a South African population. One research group 
calculated the allelic and genotypic frequencies within a South African control 
population (Esau et al., 2008) and a South African ASD population (Arieff et al., 
2010). The populations in these two studies overlapped the same Western Cape 
population pool as used in this study. ASD participants were recruited from the same 
local Cape Town government school for learners with Autism. However, both Esau et 
al. (2008) and Arieff et al. (2010) did not utilize ADOS-2 or any other ASD 
assessment to characterize their cohorts, which is the power of this current study.   
 
With regard to Esau et al. (2008), comparable genotypic frequencies of their total 
control population (all ancestry groups) were reported compared to the control cohort 
of this study. The frequencies of 61.40% for the LL homozygous genotype and 
38.60% for the LS/SS genotypes of the 5-HTTLPR only differ by 5.30% to those 
observed in this study (66.70% for LL and 33.30% for LS/SS). Therefore, this 
demonstrates that even with a small sample size of six participants without ASD, the 
control cohort in this study is representative of another control population within a 
South African context.  
 
In addition, the result of this study is comparable to the data on the frequency of the 
5-HTTLPR genotypes in another South African ASD population (Arieff et al., 2010). 
Their reported 52% frequency of homozygous LL individuals is 2.5-fold greater than 
that observed in this study (20.80%), corresponding to a 1.65-fold decrease in S-
allele containing genotypes (48.00% in Arieff et al. 2010 and 79.20% in this study). 
Although Arieff et al. (2010) reported an increased presence of the S allele in the 
ASD population compared to a control population; this difference is more 
pronounced within the ASD cohort in this study. This may be due to the use of 
ADOS-2 and strict exclusion criteria leading to a cleaner ASD phenotype; one that is 






Repeat polymorphism in the ASD endophenotypes  
The ASD endophenotypic comparisons for the 5-HTTLPR component of this study 
did not yield significant results. An increase in the S allele-containing genotypes is 
observed in the ASD-high endophenotype (n=5) compared to the control cohort, but 
this is only approaching significance (0.061). This may be a true association though, 
and should be repeated with an increased sample size for the ASD-high 
endophenotype. The lack of significance indicates that the 5-HTTLPR may play a 
role in ASD aetiology as a whole, but cannot be linked to conferring a specific trait of 
ASD or severity of this trait. Perhaps, with increased samples sizes of the 
endophenotypes, these comparisons should be repeated to determine whether the 
lack of significant association is continued. It is also possible that this locus of the 
serotonin transporter gene is not responsible for conferring susceptibility to specific 
traits of ASD, which may be more influenced by differential DNA methylation of the 
SLC6A4 promoter. 
 
4.3. SLC6A4 promoter DNA hypo-methylation  
Interestingly, investigation of the DNA methylation status of the SLC6A4 promoter 
yielded the more supportive evidence for an ASD aetiology link to serotonin 
transporter regulation. DNA methylation can be determined through a variety of 
different methods. In this study, the DNA methylation status of SLC6A4 promoter 
region, 102bp and 506bp upstream of the gene (Figure 3.3) was determined using 
bisulphite DNA sequencing and the EpiTYPER MassARRAY assay. A native 
sequence of this region was first analysed to confirm that no polymorphisms would 
interfere with DNA methylation status. Only one SNP, rs25533, with a T-C change in 
nucleotide, was identified in one control participant and one participant with ASD.  
Interestingly, the SNP identified in this study has been linked to allelic heterogeneity 
at SLC6A4 to autism susceptibility and rigid-compulsive behaviours (Sutcliffe et al., 
2005). However, according to the ADOS-2 results, the control participant 
heterozygous for this SNP does not present with any social communication or 
reciprocal social interaction impairments or repetitive and restricted behaviour. 
Therefore, the results of this study do not support an association of the SNP with any 
particular ASD trait. Notably, this SNP did not overlap with any CpG sites and 






DNA methylation analysis was carried out using two different methodologies, 
bisulphite sequencing and EpiTYPER massARRAY assay analysis. Using the 
EpiTYPER assay, the SLC6A4 promoter region (Figure 3.3) was determined to be 
hypo-methylated (Figure 3.4). DNA methylation was observed to range from 0% to 
15%, depending on the CpG site. This observed hypo-methylation may be 
responsible for the lack of evidence for DNA methylation from the qualitative method 
of bisulphite sequencing. On close inspection, the chromatogram in Appendix Figure 
B shows a small cytosine peak at CpG 4. This may be indicative of the expected low 
level of DNA methylation (2.23±2.32% from the EpiTYPER assay), but is not 
unequivocally identified because of the background noise observed in the 
chromatogram. This background noise includes small cytosine peaks that may be 
mistaken for the presence of DNA methylation.  
 
DNA methylation is generally observed at 60-90% of CpG sites in most mammals 
(Hendrich and Tweedie, 2003; Kinde et al., 2015). However, because CpG islands 
are specifically associated with hypo-methylation (Larson et al., 1992), the hypo-
methylation level of the SLC6A4 promoter region is not unexpected. The low levels 
of DNA methylation can also be explained by the presence of a number of putative 
Sp1 binding sites across the entire region investigated, with the exception of two 
CpG sites (Figure 3.3). Proteins bound to these sites can hinder access of DNA 
methyltransferases to the CpG sites. Removal of Sp1 binding sites which flank a 
CpG island can lead to de novo methylation during development (Jones and Takai, 
2001, and references within). This suggests that Sp1 transcription factors may 
impede DNA methyltransferases in gaining access to specific CpG sites. Indeed, this 
may also be true for CpG sites 3 and 37, which are not covered by Sp1 sites, as 
flanking Sp1 sites can also impede DNA methyltransferase action.   
 
In addition, the lower end (0%) of DNA methylation levels observed at the SLC6A4 
promoter could be attributed to an underrepresentation of true DNA methylation. The 
technical controls of 25% and 75% methylated DNA in the EpiTYPER assay were 
approximately 10% below the expected percentages (see Appendix Figure C). 
However, this 10% decrease likely results from an error in the percentage of 




assay, and the expected low DNA methylation levels. Zhao et al. (2013) also 
observed low levels of DNA methylation at SLC6A4, ranging from 3% to 16.7%, 
consistent with the methylation data collected in this study. Given the expected 60-
90% methylation of CpG sites (Hendrich and Tweedie, 2003; Kinde et al., 2015), the 
hypo-methylation status of the serotonin transporter promoter more than likely has a 
functional role. Therefore, any changes in the mechanisms controlling this hypo-
methylation and leading to alterations of the methylation levels may play a role in 
altering the serotonin transporter function. Only small differences are observed 
between the ASD cohort and control cohort, as well as across the endophenotypes, 
but these small differences may still play significant roles. Zhao et al. (2013) found 
significant phenotypic changes in obesity with only a one percentage change in DNA 
methylation at the SLC6A4 promoter. Therefore, a one percentage change in DNA 
methylation, as observed in this study, may indeed lead to significant phenotypic 
changes.  
 
Unfortunately, only 12 CpG regions and 21 out of 40 CpG sites in the region were 
investigated by the EpiTYPER assay (Figure 3.3), given the technical limitations of 
the assay. DNA methylation at CpG sites, 3 to 10, has previously been linked to 
SLC6A4 mRNA expression levels (Philibert et al., 2007). Within this region, only 
CpG 3, CpG 4 and CpG 10 are covered by the assay. These missing CpG sites may 
well contribute to ASD aetiology. When combined with the data from this study, they 
may add to the significance of the differential DNA methylation between ASD and 
control cohorts analysed in future studies. The CpG rich status of the SLC6A4 
promoter region investigated resulted in many fragments of equal mass, as well as 
an inadequate number of thymine residues for appropriate cleavage in the 
EpiTYPER assay. Therefore, perhaps a different technique, such as the MiSeq 
Sequencing System on an Illumina platform may prove to be more ideal. This would 
allow for a quantitative calculation of every CpG site, while concurrently allowing for 
SNP analysis.   
 
Differential SLC6A4 promoter DNA methylation in the ASD cohort 
One of the hypotheses of this study states that differential DNA methylation at the 
SLC6A4 promoter is expected between the ASD and control cohorts. This 




cohort presents with differential DNA methylation, with significantly lower DNA 
methylation levels across all 12 CpG regions over the SLC6A4 promoter compared 
to the control cohort (Figure 3.4, p=0.011). In spite of significant differences in mean 
methylation levels, significant differences were not largely observed at individual 
CpG sites. This is partly explained by the large variation in DNA methylation 
percentage observed at each site (Figure 3.4). In summary, DNA methylation was 
higher at nine of the twelve CpG sites in the control cohort compared to the ASD 
cohort. Additionally, the CpG 31/32 sites were almost completely non-methylated for 
both cohorts (0.39±1.17%). This may result from the presence of overlapping and 
flanking Sp1 binding sites, as well as the overlapping binding site of C-Ets-1 (Figure 
3.3). The transcription factor, C-Ets-1, is expressed in neural crest cells and is 
implicated in embryonic development. This is completed via RNA polymerase II 
transcription factor activity, sequence-specific DNA binding and histone 
acetyltransferase binding. The C-Ets-1 protein also interacts with other transcription 
factors and forms multi-protein complexes. It is thus implicated in typical functioning 
of the serotonin transporter by impeding the action of DNA methyltransferases from 
accessing this CpG site (Furlan and Pourtier, 2015; Li et al., 2000).  
 
Differential SLC6A4 promoter DNA methylation in the ASD endophenotypes  
This study also hypothesised that there would be differential DNA methylation at the 
SLC6A4 promoter between the ASD endophenotype comparisons and control 
cohort. This is indeed observed. Compared to the control cohort or less affected 
ASD-trait endophenotypes, significantly reduced SLC6A4 promoter DNA methylation 
was observed in the ASD-moderate endophenotype, the more severely impaired 
language endophenotypes (pre-verbal and phrase speech only) and the more 
severely affected SA and RRB endophenotypes (Figures 3.5-3.8). This corresponds 
to the significantly reduced DNA methylation levels within the ASD cohort.  
 
On the contrary, the only ASD endophenotype characterised by increased SLC6A4 
DNA methylation with increased severity of symptoms is the repetitive and restricted 
behaviour endophenotype (Figure 3.9) at the CpG 30 site.  The repetitive and 
restricted behaviour (RRB) endophenotype was of particular interest due to the 
already identified link between SLC6A4 and rigid and compulsive behaviours (Lin, 




overlaps a Sp1 binding site and therefore increased DNA methylation at this site may 
hinder the binding of Sp1. This may then, in turn, hinder transcription and therefore 
may impact upon SLC6A4 mRNA expression. The repetitive and restricted behaviour 
endophenotype also encompasses a wide range of behaviours, including stereotypic 
speech and restricted interests to unusual sensory seeking behaviours. Some of 
these behaviours are seen as coping mechanisms employed by a child with ASD in 
an uncomfortable environment as a calming influence. These repetitive behaviours 
are usually motivated by sensory seeking which can provide a child with a calm state 
(Joosten et al., 2009). Therefore, these behaviours may be a side effect of ASD and 
do not necessarily result from any change in molecular regulation. However, the 
association of significantly increased DNA methylation at the lone CpG 30 site with 
an increase in severity of repetitive and restricted behaviours implicates this site in 
the development of these behaviours. 
 
To date, there are very few studies that have looked at DNA methylation at the 
SLC6A4 promoter and therefore predicted differences in DNA methylation status are 
unexplored.  Park et al. (2015) reported elevated DNA methylation at the SLC6A4 
promoter with increased ADHD symptoms, while van Miln et al. (2014) identified 
increased ADHD symptoms with lower DNA methylation levels. This is consistent 
with a hypothesis that overall dysregulation of SLC6A4 rather than increased or 
decreased function may result in increased severity of certain traits and symptoms 
associated with neuropsychiatric disorders.  
 
Interestingly, specific CpG sites were associated with differential DNA methylation 
for certain endophenotypes. These include CpG 30 and CpG1 (both for RRB), while 
CpG 24/25 was found to be associated with ancestry groups. All of these sites 
overlap with Sp1 binding sites, while CpG24/25 is also located within a binding site 
for activating enhancer binding Protein 2 alpha (AP2-alpha). This protein is involved 
in transcription machinery recruitment (Williams and Tijan, 1991). It is expressed in 
the ectoderm, particularly the neural crest cell lineages and is involved in early cell 
differentiation and development, thus playing a role in neurodevelopment (Hilger-
Eversheim et al., 2000). Differential DNA methylation at this site could impair the 
binding of AP2-alpha and therefore alter the expression of SLC6A4 mRNA. 




ancestry groups and not ASD.  Even though only one CpG site (CpG 24/25) in this 
study exhibited ancestry-related differential methylation, it is still imperative to 
establish cohorts with equal distribution of the different ancestry groups. This will 
reduce the impact that molecular alterations based on ancestry may have on data 
acquired in further studies.  
 
Additionally, there appears to be a robust association between lower DNA 
methylation levels and impaired language (Figure 3.4). This may result from 
differential regulation of the serotonin transporter and therefore atypical levels of 
serotonin in certain regions of the brain. For instance, Johnson et al. (2016) found an 
association between language problems in preschool-aged children and prenatal 
exposure to serotonin reuptake inhibitors (SRIs). This implicates typical functioning 
of the serotonin transporter in language development. Furthermore, inhibited levels 
of serotonin in serotonergic neuron rich brain regions in mice have been associated 
with short term memory loss (Banik and Lahiri, 2004). Also, impaired or a loss of 
short term memory has long been associated with limited language. Literature shows 
that children with language impairments do significantly worse on short term and 
working memory tests (Conti-Ramsden et al., 2015 and references within). 
Therefore, this implicates atypical levels of serotonin in the development of language 
impairments, which may stem from affected short term memory. However, another 
drawback of this study is the lack of a specific language test to categorize the 
language endophenotypes. The use of the modules is sufficient as an investigatory 
approach, but further comparison statistics need to be completed on language 
endophenotypes reclassified according to specific language testing.  
 
4.4.Potential model of 5-HTTLPR and SLC6A4 promoter DNA methylation 
interplay 
When attempting to reconcile the 5-HTTLPR and the DNA methylation data for the 
SLC6A4, it appears to be contradictory. Although no significant association was 
found between the 5-HTTLPR status and DNA methylation levels, there may still be 
a link between the lowered DNA methylation levels and the S-allele containing 
genotypes. These S allele-containing genotypes are significantly enriched in the 
ASD cohort (Figure 3.1A, p=0.049), which also has significantly lowered DNA 




of the 5-HTTLPR is known to lower SLC6A4 mRNA expression, while lower DNA 
methylation of the serotonin transporter promoter leads to an increase in SLC6A4 
mRNA expression. Therefore, the decreased DNA methylation may be a ―corrective‖ 
strategy during development in an attempt to regain homeostasis and remedy the 
impaired function of SLC6A4. The same idea can be applied for the control cohort. 
The higher levels of DNA methylation within the control cohort could be a result of 
the enrichment of the L allele, in order to achieve appropriate levels of SLC6A4 
mRNA expression. This potential ―homeostasis hypothesis‖ of how both the 5-
HTTLPR and DNA methylation of the promoter region of SLC6A4 had a combined 
effect on serotonin mRNA expression is illustrated in Figure 4.1.  
 
 
Figure 4.1. Diagram illustrating potential combined effects of the 5-
HTTLPR and DNA methylation of the SLC6A4 promoter on 
serotonin transporter mRNA expression. Panel A shows the potential 
action in the control cohort, with enriched presence of the LL genotype 
and generally higher methylation, leading to intermediate levels of 5-
HTT. Panel B demonstrates the potential action in the ASD cohort with 
enriched presence of the S allele and generally lower methylation 
resulting in intermediate/higher levels of 5-HTT. Levels of expression 
are indicated using arrows (↑ is low or increased, ↑↑ is intermediate and 
↑↑↑ is high, while ↓ is decreased).   
 
However, changes in SLC6A4 mRNA expression through differential methylation 
could also result from changes in the binding of the prominent methyl-DNA-binding 
protein, the methyl-CpG-binding protein 2 (MeCP2) to the SLC6A4 promoter. MeCP2 
binds to methylated cytosine residues in gene promoter regions and can then 






Mutations in MeCP2 and subsequent altered gene expression have been linked to 
Rett syndrome, an X-linked neurological disorder, bipolar disorder, schizophrenia, as 
well as infantile ASD (Kinde et al., 2015; Lee et al., 2015). The maintenance of 
neuronal DNA methylation is essential for typical development of the mammalian 
brain and any molecular alterations of MeCP2 or its binding can lead to 
neurodevelopmental disorders, such as ASD (Kinde et al., 2015). Further analysis of 
this protein and where it binds could pinpoint or shed light on the mechanism 
responsible for differential DNA methylation at the SLC6A4 promoter.   
 
In conclusion, the data presented in this study suggest a role for atypical or altered 
serotonergic signalling within ASD aetiology. The data observed supports the 
hypothesis that there is differential molecular regulation of SLC6A4 mRNA 
expression between an ASD cohort and a control cohort, which extends to ASD 
endophenotypes. This is found for both genetic regulation, as well as epigenetic 
regulation of the serotonin transporter. However, the stronger support is for the 
involvement of the epigenetic mechanism within the development of ASD traits. This 
mechanism would likely provide the link between environmental factors and 
molecular alterations involved in ASD aetiology.  
 
Although the specific mechanisms of how DNA methylation or the repeat 
polymorphism impact directly on SLC6A4 mRNA expression are unknown, the 
combined effect of differential genetic and epigenetic regulation of the serotonin 
transporter may play a role in the aetiology of ASD. Differential regulation of the 
serotonin transporter within this ASD cohort compared to a control cohort is found. 
Therefore, an analysis of SLC6A4 mRNA transcript levels within these cohorts 
should be completed. This will allow for the establishment of how the contradictory 
actions of the 5-HTTLPR and SLC6A4 promoter DNA methylation within this ASD 
cohort affect SLC6A4 mRNA expression compared to the control cohort.  
 
The associations of differential regulation of the serotonin transporter to ASD and 
endophenotypes are an important starting point in determining to what an extent the 
development of ASD traits is linked to the 5-HTTLPR and SLC6A4 promoter DNA 
methylation. These two molecular regulatory mechanisms are potential biomarkers 
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Table A. Primer and amplicon information 
Amplicon purpose 















Table B. Participant information for the ASD and control cohorts 
 ASD cohort Control cohort 
Age 8.44±2.40 7.00±1.55 
European ancestry 44% (n=11) 100% (n=6) 
African ancestry 12% (n=3) 0% (n=0) 
Mixed ancestry 44% (n=11) 0% (n=0) 
Mean values are presented as values ± standard deviation 
  
 
Table C. Two-tailed Fisher‘s exact test p-values for each comparison of allelic and 
genotypic frequency distributions across the endophenotypes 
Significance is denoted by *, set at p<0.05. 
 
Comparison L vs. S LL vs. LS/SS H vs. L expressers 
ASD vs. control 0.100 0.049* 0.300 
ASD-mod. vs. control 0.170 0.142 0.344 
ASD-high vs. control 0.074 0.061 0.200 
ASD-mod. vs. ASD high 0.267 0.544 0.539 
Pre-verb. vs. control 0.260 0.141 0.344 
Phrase speech. vs. control 0.121 0.136 0.329 
Pre-verb./phrase speech vs. control 0.099 0.136 0.319 
Pre-verb. vs. phrase speech 0.756 1.000 1.000 
High SA vs. control 0.099 0.064 0.311 
High RRB vs. control 0.074 0.061 0.182 
High RRB vs. low RRB 0.475 0.545 0.545 





Figure A. Multiple sequence alignment in MEGA of a partial 
sequence of native DNA of the SLC6A4 promoter, upstream of the 
gene. A represents the forward and reverse sequencing reactions of 
one ASD participant, while B shows the forward and reverse 
sequencing of all six control participants. The arrow indicates the 
presence of the rs25533 SNP, with Y demonstrating a heterozygote 
genotype of TC. 
 
 
Figure B. Chromatogram showing partial sequence of the 
converted DNA of the SLC6A4 promoter, upstream of the gene. The 










Figure C. Average DNA methylation of the duplicate technical 
controls of 0, 25, 75 and 100% methylated DNA for each target CpG 
site and DNA methylation across the 12 CpG regions. The technical 
































Table D: Mann-U Whitney p-values for each comparison of CpG site and mean DNA methylation percentages across the 
endophenotypes 
Significance denoted by *, set at p<0.05 
Significance without homogeneity of variance is denoted by a
Comparison 1 3 4/10 11 24/25 26-28 29 30 31/32 33-36 37 39/40 Mean 
ASD vs. control 0.564 0.670 0.330 0.146 0.318 0.459 0.594 0.222 0.798 0.274 0.465 0.702 0.011* 
ASD-mod. vs. 
control 0.802 0.661 0.267 0.109 0.373 0.620 0.557 0.067 0.933 0.307 0.496 0.697 0.004* 
ASD-high vs. control 0.160 0.812 0.823 0.628 0.292 0.320 0.898 0.636 0.697 0.333 0.593 0.974 0.457 
ASD-mod. vs. high 0.777 0.856 0.253 0.498 0.831 0.310 0.966 0.000a 0.697 0.861 0.911 0.364 0.111 
Pre-verb. vs. control 0.265 0.405 0.503 0.133 0.534 0.451 0.473 0.344 0.965 0.165 0.314 0.695 0.004* 
Phrase speech. vs. 
control 0.553 0.924 0.315 0.240 0.160 0.522 0.772 0.161 1.000 0.933 0.628 1.000 0.026* 
Pre-verb./phrase 
speech vs. control 0.303 0.615 0.369 0.121 0.300 0.424 0.525 0.192 0.825 0.340 0.648 0.685 0.003* 
Pre-verb. vs. phrase 
speech 1.000 0.166 0.599 0.725 0.288 0.991 1.000 0.168 1.000 0.165 0.282 0.639 0.557 
High SA vs. control 0.406 0.643 0.373 0.152 0.333 0.382 0.525 0.291 0.985 0.323 0.573 0.782 0.006* 
High vs. low RRB 0.235 0.843 0.675 0.861 0.687 0.457 0.823 0.001* 0.983 0.745 0.249 0.636 0.816 
High RRB vs. 
control 0.045* 0.675 0.574 0.286 0.290 0.359 0.610 0.935 1.000 0.526 0.860 0.654 0.045* 
Ancestry 0.657 0.546 0.401 0.550 0.008* 0.216 0.684 0.659 0.640 0.792 0.852 0.755 0.080 
LL vs. LS/SS 0.457 0.358 0.532 0.190 0.935 0.516 0.422 0.868 0.966 0.959 0.212 0.395 0.445 
H vs. L expressers 0.538 0.773 0.552 0.386 0.972 0.717 0.366 0.556 0.633 0.619 0.246 0.212 0.557 






Figure D. Average DNA methylation for the CpG 24/25 sites of the 
SLC6A4 promoter for participants of African ancestry (n=14) and 
European ancestry (n=11). DNA methylation levels of the two ancestry 
populations were compared using the Mann-U Whitney test. 

























































The Molecular Autism Research in South Africa (MARSA) group (Department of Molecular 
and Cell Biology, UCT) is conducting a research that investigates how genes, social 
communication deficits, restricted and repetitive behaviours and interests are implicated in 
Autism Spectrum Disorder (ASD). This multi-disciplinary initiative includes research by 
geneticists, psychologists, clinical practitioners, and other health practitioners. We are 
gathering phenotype and genetic information from children who have the above-mentioned 
deficits or characteristics, or who have a formal or tentative diagnosis of ADHD, Dyspraxia, 
Sensory integration difficulties, Aspergers or Autism Spectrum Disorder, and invite you to 
participate in our research. 
PROCEDURES 
The genetic aspect of the study: If you agree to participate in our study, we will ask for 
cheek cell swabs from your child. The cheek swabs are painless where we will gently rub a 
sterile cotton swab across the inside of each side of your child‘s cheeks for about 30 
seconds. All samples will be taken to the MARSA laboratory where DNA will be extracted 
to examine the genetic make-up of a number of selected genes. The genes we will target 
are thought to be associated with a specific characteristic of interest. 
The non-genetic aspects of the study will be an Autism Diagnostic Observation Schedule 
(ADOS-2) assessment to identify social deficits and restricted and behaviours. This 
assessment is play-based session that will take about 1 hour to complete.  
RISKS 
There are no medical or psychological risks associated with this research.  
BENEFITS 
Although you personally will not receive any direct benefit from this project, individuals (or 
their family members, and future generations) who might develop, or have the above 
mentioned diagnosis of ASD may in the future benefit if we can locate genes associated 
with, or that lead to such disorders, or locate genes that predict responses to different 
medications. We do not expect to discover any information of direct clinical relevance to 
your condition or your treatment during the next few years. In line with the current 
regulations, we will not make the results of the genetic tests available to subjects or their 
doctors. However, the results of the play-based scoring sessions, the ADOS-2, may be 
passed on to your neuro-paediatrician or psychologist on request. 
COSTS AND COMPENSATION 
There are no costs to participants and their families in this research project.  
CONFIDENTIALITY 
We will keep your name and any other personal information we learn about you 
confidential. This information will not be given out to the repository or to anyone else. We 
will take the following steps to ensure confidentiality: a research number will be assigned 
to you when you enter the study and thereafter your name will not be used on any of the 





with your relatives, with insurance companies, or any third party not involved in research. 
When results of this study are published, your name will not be used. 
 
WITHDRAWAL FROM THE RESEARCH PROJECT 
You have the right to leave the study at any time without giving any reason, and without 
penalty. If you wish to leave the study, contact Dr Colleen O‘Ryan.  
 
CONTACTS 
If you have any questions about the study, you may contact Dr O‘Ryan at 
genetics.kidslab@gmail.com or 021 650 2457. 
 
PARTICIPATION 
I give consent for my child to participate in the following aspects of this study: 
 Provide cheek swabs and participate in the play-based assessment 
(ADOS-2)* which I consent to have recorded on video tape/DVD**  Yes / 
No     
 
 Contact you for future research       Yes /No 
 
* A familiar educator/carer is given permission to be present during the ADOS if the learner is pre-verbal / uses 
single or phrase speech words only 
**The video will used for scoring the assessment, is kept strictly confidential and the children’s identities will not 
be revealed;  
If you sign below, it means that you have read (or have had read to you) the information given in this 
consent form, and you would like to be a volunteer in this study. 
 
Parent / Guardian Name:     Child‘s Name:  
Email:       Tel: 
Signature:      Date: 
Signature of Principal Investigator:     Date: 
Witness:      Date 
 
